- Home
- LPCN vs FSEA Comparison
LPCN vs FSEA Comparison
Compare LPCN & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPCN | FSEA |
|---|---|---|
| Founded | 1997 | 1890 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 56.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LPCN | FSEA |
|---|---|---|
| Price | $10.45 | $12.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 226.3K | 3.6K |
| Earning Date | 03-12-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,322,693.00 | ★ $14,753,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 29.53 |
| 52 Week Low | $2.52 | $9.95 |
| 52 Week High | $12.37 | $15.00 |
Technical Indicators
Market Signals| Indicator | LPCN | FSEA |
|---|---|---|
| Relative Strength Index (RSI) | 73.57 | 53.74 |
| Support Level | $9.30 | $12.65 |
| Resistance Level | $12.37 | $13.00 |
| Average True Range (ATR) | 1.09 | 0.21 |
| MACD | 0.11 | -0.03 |
| Stochastic Oscillator | 71.14 | 49.37 |
Price Performance
Historical ComparisonAbout LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.